Richard Labaudinière is a renowned pharmaceutical scientist in the area of protein misfolding. He has more than 30 years’ experience in senior leadership positions in the pharmaceutical and biotechnology industries, most recently as CEO of FoldRx Pharmaceuticals. Under his leadership, FoldRx Pharmaceuticals developed the drug tafamidis (Vyndaqel®), a disease-modifying therapy for the treatment of transthyretin-related hereditary amyloidosis, a rare but deadly neurodegenerative disease caused by protein misfolding. FoldRx was acquired by Pfizer in 2010. At Glaxo, he led the preclinical program to discover, optimize, and develop the PDE5 enzyme inhibitor tadalafil (Cialis®, Adcirca®) currently used for the treatment of erectile dysfunction (ED), of pulmonary arterial hypertension, and symptoms of benign prostatic hyperplasia (BPH). Dr. Labaudinière holds a PhD in organic chemistry from the Ecole Nationale Supérieure de Chimie de Montpellier in France.